Adding pertuzumab to standard of care improved survival by 17% in patients with early-stage HER2-positive breast cancer.

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their ...

T-DXd monotherapy and T-DXd plus pertuzumab continue to show robust efficacy in HER2-positive metastatic breast cancer.

Christopher Schenewerk, MD, discussed his history with alcohol abuse and how he works to break down the taboo of substance ...

During a live event, Shuo Ma, MD, PhD, discussed the outcomes of the BRUIN trial of pirtobrutinib in BTK inhibitor–pretreated ...

In an interview with Targeted OncologyTM, Dong Chen, MD, PhD, hematopathologist and vice chair of practice in pathology in the Department of Laboratory Medicine and Pathology at Mayo Clinic in ...

THE001, a thermosensitive doxorubicin liposome for soft tissue sarcomas, received FDA orphan drug designation, offering ...

Branding in the health care industry should prioritize communicating empathy and care through every touchpoint.

Panelists discuss how the choice between hydroxyurea (HU) and interferon (IFN) for cytoreductive therapy in polycythemia vera ...

Jack Khouri, MD, discusses data from a multicenter study of teclistamab in patients with relapsed/refractory multiple myeloma who had prior exposure to BCMA-directed therapy.

Panelists discuss how steroid dosing for chronic graft-vs-host disease (cGVHD) typically starts at 0.5-1 mg/kg/day depending on severity, with careful tapering to avoid flares.

Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.